Zydus Cadila launches ‘Ujvira’ to treat breast cancer
May 24, 2021
Treatment cost to come down by 80% for the patients
In a breakthrough in breast cancer treatment, pharma major Zydus Cadila (Cadila Healthcare Limited) on Monday announced the launch of Trastuzumab Emtansine, the first Antibody Drug Conjugate (ADC) biosimilar, which is considered a highly effective drug for treating both early and advanced HER2-positive breast cancer. The company launched the product under the brand name ‘Ujvira’.
The human epidermal growth factor receptor 2 (HER2)-positive breast cancer is considered an aggressive form and constitutes 20 to 25% of all breast cancers, the company informed, adding that its new product can reduce the treatment cost by almost 80 per cent.
Zydus launches Ujvira, a breakthrough in Breast Cancer treatment
equitybulls.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from equitybulls.com Daily Mail and Mail on Sunday newspapers.
Zydus brings world s first biosimilar ADC for breast cancer treatment
biospectrumindia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospectrumindia.com Daily Mail and Mail on Sunday newspapers.
Top Pharmaceutical Companies in India
In this article we will take a look at the top 15 pharmaceutical companies in India. You can skip our detailed analysis of the pharma industry’s outlook for 2021, and some of the major growth catalysts for pharmaceutical stocks, and go directly to the
Since late 2019, after the world was caught off-guard owing to the COVID-19 pandemic, the pharma industry has taken the center stage as they raced to develop and produce vaccines. Medicines being an essential requirement, the pharmaceuticals industry has always been the vital resource and the safest stock market sector for the public, but with this recent worldwide health crisis, the importance of this industry has become more pronounced than ever. During the inception of the pandemic, drug makers, including the 15 largest drug companies in the world, were confronting the coronavirus on one hand while on the other hand, they were barging through uncertainty regarding research and development.